Loading clinical trials...

COMPLETEDPHASE4

Iota-Carrageenan Nasal Spray in Common Cold

Efficacy and Safety of Iota-Carrageenan Nasal Spray 1.2 g/l (0.12 Percent) (Bisolviral) Versus Placebo Nasal Spray in the Early Treatment of Common Cold

NCT01944631•Boehringer Ingelheim

View on ClinicalTrials.gov

Summary

The aim of this clinical trial is to investigate the effect of Iota-Carrageenan treatment on cold symptoms. The effect of treatment on the duration of the cold and the patients viral load plus cytokine level indicating the inflammatory response will be analyzed.

Eligibility

Age

18 - 64 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patients consider that they are in an early stage of common cold with symptoms of no more than 48 hours duration
•Symptom score of equal or more than 1 for for at least one of the symptoms sore throat, runny nose and blocked nose on a 0-3 verbal rating scale
•Total symptom score of equal or less 9 for symptoms headache, muscle ache, chilliness, sore throat, blocked nose, runny nose, cough, and sneezing measured on a 0-3 verbal rating scale
•Patients agree to refrain from taking any products intended to prevent, intervene in, or treat cough/colds/flu, starting at study entry and continuing through day 10 (e.g. those containing zinc, Echinacea); use of a daily multivitamin is allowed.

Exclusion Criteria

•Known hypersensitivity or are allergic to any component of the test device
•Clinically significant cardiovascular, endocrinological, neurological, respiratory, gastrointestinal disease or history or any current disease that is considered by the investigator as a reason for exclusion e.g. current allergic rhinitis, chronic obstructive pulmonary disease
•Severe nasal septum deviation or other condition that could cause nasal obstruction such as the presence of nasal polyps.
•History of nasal or sinus surgery that in the opinion of the investigator may influence symptom scores
•Taking any prescribed medication other than for contraception, that is considered by the investigator as a reason for exclusion e.g. systemic steroids, intranasal medicines, antibiotics
•Common cold or flu like symptoms for more than 48 hours.
•Recent (within the previous 2 days) intake of a common cold medicine that in the opinion of the investigator may influence symptom scores (analgesics, nasal decongestants, cough medicines)
•Current smoker (more than 10 cigarettes a day)

Locations (1)

1326.1.44001 Boehringer Ingelheim Investigational Site

Cardiff, United Kingdom

Key Dates

Start Date

September 1, 2013

Primary Completion Date

March 1, 2014

Completion Date

March 1, 2014

Last Updated

April 3, 2015

Enrollment

200

ACTUAL participants

Conditions

Common Cold

Interventions

Placebo

DEVICE

Iota-Carrageenan

DEVICE

Efficacy and Safety in the Combination of Ibuprofen / Loratadine Versus Ibuprofen Versus Loratadine

NCT06531707

Common Cold

View study

COMPLETEDPHASE4

A Clinical Evidence Study Evaluating Quality of Life Parameters Following Treatment With Robitussin

NCT06716645

Common ColdCough

View study

UNKNOWN

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 3, 2015Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Iota-Carrageenan Nasal Spray in Common Cold

Inclusion Criteria

Exclusion Criteria

Efficacy and Safety in the Combination of Ibuprofen / Loratadine Versus Ibuprofen Versus Loratadine

A Clinical Evidence Study Evaluating Quality of Life Parameters Following Treatment With Robitussin

Commercially Available Cannabis Products for Immune Support

Active and Placebo Controlled Study to Test the Efficacy and Safety of an Aspirin-Lidocaine Lozenge in the Symptomatic Treatment of Sore Throat Associated With a Common Cold

A Study of Olynth Saline/Ectomed Nasal Drops/Spray Based Upon Previous Usage

Prophylactic Treatment With Carragelose Nasal Spary to Prevent SARS-CoV-2, COVID-19, Infections in Health Care Workers